PHARMACEUTICAL THERAPEUTIC SUBSTANCES
| Brand | Owner (click to sort) | Address | Description |
|---|---|---|---|
| KV | LUMARA HEALTH IP LTD. | 300 Delaware Avenue, Suite 1270 Wilmington DE 19801 | Pharmaceutical and therapeutic substances for the treatment of menopause and post menopause symptoms and conditions, miscarriage, preterm labor, preterm birth, abnormalities and complications of pregnancy and abnormalities, complications of labor and delivery, and hormone-related conditions, excluding nutritional supplements for copulative health and sexual enhancement, vitamins for copulative health and sexual enhancement, pharmaceutical and therapeutic substances for copulative health and sexual enhancement, and medical and surgical lubricants; |
| KV PHARMACEUTICAL | LUMARA HEALTH IP LTD. | 300 Delaware Avenue, Suite 1270 Wilmington DE 19801 | Pharmaceutical and therapeutic substances for the treatment of menopause and post menopause symptoms and conditions, miscarriage, preterm labor, preterm birth, abnormalities and complications of pregnancy and abnormalities, complications of labor and delivery, and hormone-related conditions, excluding nutritional supplements for copulative health and sexual enhancement, vitamins for copulative health and sexual enhancement, pharmaceutical and therapeutic substances for copulative health and sexual enhancement, and medical and surgical lubricants;PHARMACEUTICAL; |
| THER-RX | LUMARA HEALTH IP LTD. | 300 Delaware Avenue, Suite 1270 Wilmington DE 19801 | pharmaceutical and therapeutic substances for the treatment of menopause and post menopause symptoms and conditions, miscarriage, preterm labor, preterm birth, abnormalities and complications of pregnancy and abnormalities, complications of labor and delivery, and hormone-related conditions; |
Where the owner name is not linked, that owner no longer owns the brand |
Technical Examples
- This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as pharmaceutical agents or compositions that can be administered to humans and other mammals. Useful compositions include biological agents such as nucleic acids, proteins, lipids and cytokines. Conjugates can also be used to monitor the pathway and half-life of pharmaceutical composition in vivo and for diagnostic, therapeutic and prophylactic purposes. The invention also relates to kits comprised of agents and conjugates that can be used for the detection of diseases, disorders and nearly any individual substance in a complex background of substances.